How COVID-19 is Redefining Drug Development & Manufacturing

How COVID-19 is Redefining Drug Development & Manufacturing

Monday, March 29, 2021 2:20 PM to 2:40 PM · 20 min. (Africa/Abidjan)

Antibodies

Keynotes: Antibodies

Presentation

Information

Unprecedented challenging time also provides opportunities for great advancement of innovation with cooperation. In this session, learn about

Close collaboration and communication with all stakeholders, utilizing the latest technology, establishing a robust business contingency plan and eliminating a lead time to deliver drugs on time stably
Accelerate timelines by streamline process
Few case studies of our innovation to deliver drugs in just 3 months and how Samsung Biologics goes extramile

Chris McPherson, Senior Scientists and Technical Advisor for Upstream & Downstream Manufacturing, Samsung Biologics

Samsung BiologicsSamsung Biologics is a fully integrated CDMO partner providing highly tailored solutions to each client. Our end-to-end services include upstream and downstream process development, clinical and commercial manufacturing, aseptic fill/finish, and analytical and biosafety testing—all from a single location. Our plants are cGMP compliant holding 364KL total capacity with wide range of 1KL, 5KL, 15KL scale bioreactors. To meet the growing market demand, we are currently expanding manufacturing capacity with the new plant 4 with additional 264KL.

Log in

See all the content and easy-to-use features by logging in